Chr	Start	End	Ref	Alt	Ref.Gene	Func.refGene	ExonicFunc.refGene	Gene.ensGene	avsnp150	clinvar: Clinvar	VIC: VIC and Evidence	AAChange.ensGene	AAChange.refGene	AAChange.knownGene	Freq_ExAC_ALL	Freq_esp6500siv2_all	Freq_1000g2015aug_all	Freq_gnomAD_AF	FATHMM_pred	CADD_phred	SIFT_score	GERP++_RS	Polyphen2_HDIV_pred	dbscSNV_ADA_SCORE	dbscSNV_RF_SCORE	Interpro_domain	MetaSVM_score	MutationTaster_pred	Freq_ExAC_POPs	Freq_gnomAD_exome_POPs	OMIM	Phenotype_MIM	OrphaNumber	Orpha	cgi_info	civic_info	Otherinfo
7	55259515	55259515	T	G	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs121434568	 clinvar: 7 	 VIC: Uncertain significance EVS=[0, 1, NONE, NONE, 0, 0, 2, 2, 2, NONE] 	ENSG00000146648:ENST00000455089:exon20:c.T2438G:p.L813R,ENSG00000146648:ENST00000275493:exon21:c.T2573G:p.L858R,ENSG00000146648:ENST00000454757:exon21:c.T2414G:p.L805R	EGFR:NM_001346941:exon15:c.T1772G:p.L591R,EGFR:NM_001346897:exon20:c.T2438G:p.L813R,EGFR:NM_001346899:exon20:c.T2438G:p.L813R,EGFR:NM_001346898:exon21:c.T2573G:p.L858R,EGFR:NM_001346900:exon21:c.T2414G:p.L805R,EGFR:NM_005228:exon21:c.T2573G:p.L858R	EGFR:uc022ado.1:exon2:c.T278G:p.L93R,EGFR:uc010kzg.2:exon20:c.T2438G:p.L813R,EGFR:uc022adn.1:exon20:c.T2438G:p.L813R,EGFR:uc003tqk.3:exon21:c.T2573G:p.L858R,EGFR:uc011kco.2:exon21:c.T2414G:p.L805R,EGFR:uc022adm.1:exon21:c.T2573G:p.L858R	.	.	.	7	D	33	0.0	5.71	D	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	0.987	D	AFR:., AMR:., FIN., NFE:., SAS:., OTH:.	AFR:7, AMR:7, ASJ7, EAS7, FIN7, NFE:7, SAS:7, OTH:7	131550	211980;616069;	294023; 	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~null~	.	EGFR, L858R, Lung Adenocarcinoma, Gefitinib, Predictive, Does Not Support, B, Reduced Sensitivity, In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704)., Urata et al., 2016, J. Clin. Oncol.
1	241663903	241663904	GA	-	FH	intronic	.	ENSG00000091483	rs879069854	 clinvar: 1 	 VIC: Strong clinical significance EVS=[2, 1, 1, NONE, 1, 2, 2, 2, 2, 1] 	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	AFR:., AMR:., FIN., NFE:., SAS:., OTH:.	AFR:1, AMR:1, ASJ1, EAS1, FIN1, NFE:1, SAS:1, OTH:1	136850	150800;606812;	24;523; 	24|Fumarase deficiency|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|606812 ~523|Familial leiomyomatosis and renal cell cancer<br>Familial leiomyomatosis cutis et uteri<br>Familial leiomyomatosis with renal carcinoma<br>Familial multiple cutaneous leiomyomas<br>HLRCC<br>Hereditary leiomyomatosis<br>Hereditary leiomyomatosis with renal carcinoma<br>Hereditary multiple cutaneous leiomyomas<br>MCUL<br>Multiple cutaneous and uterine leiomyomas<br>Reed syndrome|Unknown|Autosomal dominant|Adolescent<br>Adult<br>Elderly|150800 ~null~	.	.
